Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rakesh Jain

Psychiatry Lake Jackson, TX Medical Doctor

NPI 1124221304 CMS profile 232968

461 This Way St, Lake Jackson, TX 77566

Open in the dashboard

General payments

$7,226,440

7,234 records reported · program years 2019–2025

Research payments

$3,980

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rakesh Jain of Lake Jackson, TX is reported in the CMS Open Payments database as having received $7,226,440 across 7,234 general payments and $3,980 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,457,154 1,315
2024 General $1,170,656 1,143
2023 General $1,296,859 1,179
2023 Research $3,980 2
2022 General $1,095,034 1,161
2021 General $753,390 649
2020 General $570,327 531
2019 General $883,020 1,256

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rakesh Jain
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Rakesh Jain were reported at $1,457,154. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Rakesh Jain Psychiatry median Middle half National median
2019 $883,020 $184 $59–$605 $163
2020 $570,327 $119 $36–$372 $114
2021 $753,390 $143 $43–$576 $132
2022 $1,095,034 $153 $50–$590 $149
2023 $1,296,859 $170 $56–$651 $160
2024 $1,170,656 $179 $57–$673 $164
2025 $1,457,154 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $983,697 839 payments
  2. Alkermes, Inc. $741,343 696 payments
  3. Neurocrine Biosciences, Inc. $738,709 728 payments
  4. AbbVie, Inc. $724,655 758 payments
  5. ITI, Inc. $710,669 661 payments
  6. Otsuka America Pharmaceutical, Inc. $672,283 847 payments
  7. Axsome Therapeutics, Inc. $588,477 583 payments
  8. Allergan Inc. $248,910 299 payments
  9. Janssen Pharmaceuticals, Inc $238,040 288 payments
  10. Supernus Pharmaceuticals, Inc. $226,870 238 payments
  11. Other $1,352,787 1,297 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,659,944 1,701 payments
  2. Consulting Fee $1,448,650 429 payments
  3. Travel and Lodging $672,148 2,700 payments
  4. Honoraria $312,104 143 payments
  5. Food and Beverage $111,481 2,249 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $22,024 7 payments
  7. Education $89 5 payments
Products named General payments · program years 2019–2025
  1. REXULTI $674,719 847 payments
  2. Auvelity $569,183 573 payments
  3. VRAYLAR $557,405 592 payments
  4. AUSTEDO $523,270 438 payments
  5. CAPLYTA $505,140 480 payments
  6. INGREZZA $487,325 451 payments
  7. LYBALVI Cns $432,399 380 payments
  8. LYBALVI Cns $404,629 349 payments
  9. LYBALVI Cns $404,586 348 payments
  10. LYBALVI Cns $404,586 348 payments
  11. Other $4,208,566 4,416 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $3,980 2 payments

Records

7,236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record